(RTTNews) - Arvinas (ARVN) announced the submission of a New Drug Application to the FDA with its partner Pfizer (PFE), for vepdegestrant for the treatment of patients with ER+/human epidermal growth factor receptor 2-negative ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. The submission is based on results from VERITAC-2, a global, randomized Phase 3 trial evaluating vepdegestrant versus fulvestrant.
Vepdegestrant is being jointly developed by Arvinas and Pfizer for the treatment of patients with advanced or metastatic ER+/HER2- breast cancer and was granted fast track designation as a monotherapy by the FDA.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
